Shark tank fame Namita Thapar to rake in Rs 127 crore through Emcure Pharma IPO

Shark Tank fame Namita Thapar, part of the promoter group of Emcure Pharmaceuticals, will make around Rs 127 crore through the IPO, which will kick off on July 3. The issue closes on July 5.

Thapar, who had acquired shares in Emcure at a weighted average price of Rs 3.44 apiece, will offload a partial stake of about 12.68 lakh shares under the offer for sale (OFS) component through the IPO.

Considering the upper price band of Rs 1,008, the stake sale will fetch around Rs 127 crore. As of March 2024, Thapar holds about 63 lakh shares or 3.5% in the company.


The IPO comprises a fresh issuance of equity shares worth Rs 800 crore and an OFS of 1.14 crore equity shares by promoters and existing shareholders. Others who are also giving up their stakes under the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital.

Proceeds of the fresh issue will be used towards payment of debt and for general corporate purposes.

Pune-based firm Emcure Pharma is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

The research and development-driven company with a differentiated product portfolio that includes orals, injectables, and biotherapeutics with target markets across over 70 countries, including a presence in India, Europe, and Canada.

The global pharmaceutical market is expected to sustain growth at a compound annual growth rate of approximately 5.0% to 5.5% between the calendar years 2023 and 2028, to reach approximately $1,900 billion (approximately Rs 157 lakh crore) to $1,950 billion (about Rs 161 trillion) in the calendar year 2028.

In FY24, the company's revenue from operations grew 11% year-on-year (YoY) to Rs 6,658 crore from Rs 5,985 crore in the preceding financial year. Meanwhile, profit after tax declined 6% year-on-year to Rs 527 crore from Rs 562 crore a year earlier.

Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JPMorgan India are the book-running lead managers to the issue.